GSK Unit Pushes Back On SEC In Stock Fraud Suit
Stiefel Laboratories Inc. pushed back Friday in Florida federal court against the U.S. Securities and Exchange Commission's bid for a win on claims that the pharmaceutical company and its ex-CEO defrauded...To view the full article, register now.
Already a subscriber? Click here to view full article